Developed by CSL in collaboration with the Australian government, Panvax is intended for use in the prevention of influenza caused by a pandemic strain of avian influenza virus.
CSL is said to be the only vaccine supplier that manufactures influenza vaccines in Australia. Through its recent and continuing investment of more than $80m in Fluvax (a vaccine against seasonal influenza) CSL remains committed to the ongoing provision of influenza vaccines to the Australian community.
Mary Sontrop, general manager of CSL Biotherapies, a group member company of CSL and the business unit responsible for developing and manufacturing Panvax, said: “In the event of a pandemic, CSL will rapidly gear up to manufacturing levels that will ensure all Australians have access to safe, effective coverage against avian flu. We continue to work collaboratively with the World Health Organization and with the Australian scientific community to maintain a high level of avian flu preparedness.”